Syngene International declares ₹1.25 dividend, appoints new directors
Syngene International Limited held its 33rd AGM on July 29, 2026, declaring a final dividend of ₹1.25 per share for FY26. The meeting approved the appointment of S.R. Batliboi & Associates LLP as statutory auditors, replacing B S R & Co. LLP. Shareholders also appointed Dr. Vijaya Chandru and Dr. Arun Chandavarkar as Independent Directors and reappointed Professor Catherine Rosenberg.

*this image is generated using AI for illustrative purposes only.
Syngene International Limited declared a final dividend of ₹1.25 per equity share for the financial year ended March 31, 2026, during its 33rd Annual General Meeting (AGM) held on July 29, 2026. The meeting, conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM), also approved significant changes to the Board of Directors and the appointment of a new statutory auditor, marking a transition in the company’s governance structure for the upcoming fiscal period.
The AGM commenced at 3:31 pm (IST) with 117 members present. The proceedings were overseen by Ms. Kiran Mazumdar-Shaw, Executive Chairperson, and Mr. Siddharth Mittal, Managing Director and Chief Executive Officer. In compliance with the Companies Act, 2013 and SEBI Listing Regulations, the company facilitated remote e-voting from July 24, 2026, to July 28, 2026, allowing shareholders to cast their votes on all nine resolutions proposed.
Key Resolutions Approved
The ordinary business items included the adoption of the audited standalone and consolidated financial statements for FY26. Alongside the financial statements, the Board recommended the final dividend payout. The special business agenda focused on board composition and auditor appointments.
| Resolution Category | Key Outcome | Details |
|---|---|---|
| Dividend | Final Dividend Declared | ₹1.25 per equity share for FY26 |
| Auditor Appointment | New Statutory Auditor | S.R. Batliboi & Associates LLP appointed; B S R & Co. LLP outgoing |
| Board Appointments | Independent Directors | Dr. Vijaya Chandru and Dr. Arun Chandavarkar appointed |
| Board Reappointments | Director Rotation | Professor Catherine Rosenberg retired by rotation and reappointed |
| Management | MD & CEO Approval | Mr. Siddharth Mittal’s appointment and remuneration approved |
Governance and Leadership Changes
A notable shift occurred in the audit function, with M/S S.R. Batliboi & Associates LLP (ICAI Firm Registration Number: 101049W/E300004) appointed as the Statutory Auditors, succeeding B S R & Co. LLP. Mr. Ankit Mittal, Partner at S.R. Batliboi & Associates LLP, attended the meeting as the incoming auditor.
The Board composition was updated with the appointment of Dr. Vijaya Chandru and Dr. Arun Chandavarkar as Independent Directors. Ms. Vinita Bali was recommended for appointment as a Non-Executive Director. Professor Catherine Rosenberg, who retired by rotation, was reappointed as a director. The remuneration payable to Mr. Siddharth Mittal in his capacity as Managing Director and CEO was also approved by the shareholders.
Analytical Observation
The simultaneous appointment of two new Independent Directors and a change in statutory auditors suggests a strategic refresh of the company’s oversight mechanisms. This aligns with regulatory expectations for enhanced corporate governance in listed entities. The declaration of a consistent final dividend of ₹1.25 per share, despite the transition in audit firms, signals management’s confidence in the company’s cash flow stability and commitment to shareholder returns for FY26.
Historical Stock Returns for Syngene International
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.25% | +0.24% | -4.58% | -13.75% | -40.01% | -34.08% |
How might the transition from B S R & Co. LLP to S.R. Batliboi & Associates LLP impact Syngene's future audit timelines or compliance reporting standards?
What specific expertise do the newly appointed Independent Directors, Dr. Vijaya Chandru and Dr. Arun Chandavarkar, bring that could influence Syngene's strategic direction in the CRO sector?
Given the consistent dividend payout, does management anticipate any changes to capital allocation strategies or investment in R&D for the upcoming fiscal year?


































